Reaching over 100 patient cases with the PURE EP System demonstrates BioSig Technologies, Inc.'s progress in the electrophysiology market. This milestone could be seen as evidence of the product's efficacy and market acceptance, potentially leading to increased sales and positive investor sentiment. The direct mention of BSGM and the focus on a significant achievement for its product suggests a high relevance and importance to the company's stock. The positive score reflects the expectation of a favorable short-term impact on BSGM's stock price.